Kornimate/medical-research-clean huggingface dataset:
handwriting analysis in movement disorders

Conditions: Movement Disorders; Parkinson Disease; Writing Disorder

Summary: handwriting is a complex cognitive prowess that deteriorates in patients affected by neurodegenerative diseases, including movement disorders. more in detail, patients with parkinson's disease (pd) may manifest prominent handwriting abnormalities which have been collectively identified as parkinsonian micrographia. micrographia may manifest at the onset of the disease and then worsens progressively with time. previous techniques released to investigate micrographia in pd relied on perceptual analysis of simple tasks or were based on expensive technological tools, including tablets. however, handwriting can be promptly collected in an ecological scenario, through safe, cheap, and largely available tools. also, the objective handwriting analysis through artificial intelligence would represent an innovative strategy even superior to previous techniques, since it allows for the analysis of large amounts of data. in this experimental project, the investigators apply a specific machine learning algorithm to analyze handwriting samples recorded in healthy controls and pd patients. the study aims to verify whether the technique proposed by the investigators would be able to detect parkinsonian micrographia objectively, monitor the evolution of handwriting abnormalities and assess the symptomatic improvement of handwriting following l-dopa administration in pd patients.


Eligibility criteria:
inclusion criteria: * healthy conditions * clinical diagnosis of parkinson's disease exclusion criteria: * cognitive decline
dose-effect relation of salivary gland irradiation

Conditions: HNSCC

Summary: optimization of radiotherapy to reduce xerostomia is difficult, because many gland locations cannot be seen with current imaging modalities and biological dose-effect are currently insufficiently understood. psma pet is a new diagnostic instrument which can visualize the presence of vital acinar cells in salivary gland locations throughout the head and neck, with a sensitive and quantitative signal. a reduction of psma accumulation in salivary glands is thought to correlate with loss of vital acinar cells. the pet images can be correlated with radiotherapy dose distributions in gland-based or voxel-based evaluations. this makes psma pet a suitable instrument to derive the radiobiological dose-effect relations that are required to develop better and gland-specific dose constraints for radiotherapy. the results of this study can contribute to lower toxicity and better quality of life in patients treated with high-dose radiotherapy in the head and neck.

primary objective of this prospective observational study is to determine the gland-based dose-effect relation between conventionally fractionated radiotherapy (rt) and long-term loss of acinar cells, per salivary gland type. the study population consists of a maximum of 20 patients with hnscc referred for high-dose (cc)rt. there is no therapeutic intervention. diagnostic intervention is psma pet/ct.

Eligibility criteria:
inclusion criteria: * hnscc of the head-neck area, ctx-4 n0-3 m0 * accepted for ebrt in a conventionally fractionated schedule of 6-7 weeks. exclusion criteria: * age \<18y * pregnancy or lactation * participation in conflicting studies, e.g. with non-standard treatment and/or imaging * inability to provide informed consent

Keywords: head-neck tumours radiotherapy salivary gland toxicity psma pet/ct
echocardiography in men with erectile dysfunction

Conditions: Erectile Dysfunction; Cardiovascular Diseases; Cardiac Disease

Summary: cardiovascular disease is the leading cause of morbidity and mortality in the world. to curb disease development, there is, therefore, a need to identify more people at increased risk. this can be done by advanced echocardiography, where the exact contraction pattern and dimensions of the heart are measured. one group of patients who are already considered to be at increased risk for later development of heart disease are men with erectile dysfunction. the investigators goal is to study the early detection of cardiac dysfunction in men with erectile dysfunction using both conventional and advanced echocardiography to analyze the possibility of preventing serious cardiovascular disease.

cardiovascular disease is the leading cause of morbidity and mortality across the globe. about 524,000 danes live with cardiovascular disease and it affects approx. 56,400 people. in addition, many people live with heart problems without knowing it. these figures emphasize the importance of early identification of more people at increased risk of developing cardiovascular disease to prevent morbidity and mortality. this can be done using advanced echocardiography, where the heart's precise contraction pattern, as well as structure and dimensions, are measured. one group of patients who are already considered to be at increased risk for later development of cardiovascular disease are men with erectile dysfunction (ed). ed is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. approximately 30% of men over the age of 40 are affected by ed, and the incidence increases with age. ed is thought to be a precursor to cardiovascular disease, where it has been proven that after the onset of erection problems, over 3-5 years, there is an approximately 50% increased risk of cardiovascular disease. the investigators hypothesize that cardiac structure and function assessed by conventional and advanced echocardiography together with cardiac biomarkers are abnormal in patients diagnosed with erectile dysfunction and can identify patients at high risk for cardiovascular complications. echocardiography can serve as an important tool in risk assessment in these men who do not necessarily have symptom-causing problems.

Eligibility criteria:
inclusion criteria: * men above 40 years old diagnosed with ed will be eligible to participate if none of the exclusion criteria below are present. exclusion criteria: * patients not able to cooperate * patients unable to understand and sign "informed consent" * previous pelvic surgery (including prostatectomy, cystectomy and rectal surgery) * neurological diseases (e.g. multiple sclerosis, spinal cord injury) * ed following pelvic trauma

Keywords: echocardiography 3d echocardiography strain rate imaging tissue doppler speckle tracking
a trial of thalidomide and capecitabine in metastatic renal cell carcinoma

Conditions: Kidney Neoplasms

Summary: the purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination.


Eligibility criteria:
inclusion criteria:- able to comprehend and sign an irb approved informed consent * willingness and ability to comply with the fda-mandated s.t.e.p.s.® program. * male or female 18 years or older * willing to use contraception * pathologic diagnosis of renal cell carcinoma * bi-dimensionally measurable disease * evidence of disease progression prior to start of treatment * failed prior immunotherapy or unwilling/unable to receive prior immunotherapy * adequate hematologic data: anc.1.5; platelets\>100x10\^9 * adequate renal function: creatinine clearance .50cc * adequate liver function: alkaline phos \<3xuln ast/alt \<3xuln t.bili \<1.5xuln * ecog performance status 0-1 exclusion criteria:- known brain metastases. * peripheral neuropathy. * pregnant and/ or lactating female. * unable to take a baby aspirin.
a study in people with high cholesterol

Conditions: Hypercholesterolemia

Summary: the purposes of this study are to determine: * the safety of the study medication and any side effects that might be associated with it * whether the study medication can help patients with high levels of "bad" cholesterol (low-density lipoprotein-cholesterol \[ldl-c\]), alone or in combination with additional study medication


Eligibility criteria:
inclusion criteria: * men and women between 18 and 80 years of age * people with abnormal cholesterol levels exclusion criteria: * people with diabetes * people whose blood pressure \>160/95 mm hg, on or off blood pressure medicine * people who have had frequent chest pain or unstable angina, a heart attack or a heart procedure including stent placement, within the past 3 months
anti-cancer potentiality of saffron against hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: saffron has recently gained considerable interest for its capacity to interfere with cancer at initiation and promotion stages as well as for cancer treatment. although saffron and its constituents have been shown to have antitumorigenic and proapoptotic activities in different cancer cell lines. the aim of the current investigation is to identify the anti-cancer potentiality of saffron on hepatocellular carcinoma patients.

hepatocellular carcinoma (hcc) is the fifth most common cancer and the third leading cause of cancer mortality in the world. chronic infection with hepatitis b and c is the major risk factors for hcc worldwide. other factors that contribute to the formation of hcc include exposure to environmental carcinogens, iron overload, fatty liver disease, and alcohol abuse. there has been a sustained rise in its incidence in both developing and developed countries. despite the growing therapeutic options for patients with cancer, their efficacy is time-limited and non-curative. hence to overcome these drawbacks, an incessant screening for superior and safer drugs has been ongoing for numerous decades, resulting in the detection of anti-cancer properties of several phytochemicals. chemoprevention using readily available natural substances from vegetables, fruits, herbs and spices is one of the significantly important approaches for cancer prevention in the present era. among the spices, saffron has generated interest because pharmacological experiments have established numerous beneficial properties including radical scavenging, anti-mutagenic and immuno-modulating effects. saffron is a naturally derived plant product from the dried stigma of the crocus sativus flower (family iridaceae) that may have biologically useful properties. in fact, saffron extract and its biologically active compounds, including crocin, crocetin, carotene, and safranal, have been shown both in vitro and in vivo to possess antioxidant, anticancer, anti-inflammatory, and memory-improving properties. saffron is also used in folk medicine as an antispasmodic, antidepressant, and aphrodisiac. furthermore, it is one of the most commonly used species around the world for flavouring and colouring foods. saffron has recently gained considerable interest for its capacity to interfere with cancer at initiation and promotion stages as well as for cancer treatment. although saffron and its constituents have been shown to have antitumorigenic and proapoptotic activities in different cancer cell lines.

Eligibility criteria:
inclusion criteria: * adult male and female patients above 18 years * patients with end-stage hcc not candidate for curative, loco regional treatment and /or systemic chemotherapy * patients with available baseline laboratory parameters and contrast- enhancing images after given written consent for research participation. exclusion criteria: * patients who are candidate for curative and/or loco-regional or combination treatment for hcc * patients with concomitant malignancies other than hcc

Keywords: saffron
a study to evaluate the efficacy of axs-05 compared to bupropion in preventing the relapse of depressive symptoms

Conditions: Major Depressive Disorder

Summary: this is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of axs-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (mdd) who have responded to treatment with axs-05.

eligible subjects will receive open-label axs-05 during the 10-week open-label treatment period, during which they will be monitored for response and remission. subjects meeting the response and remission criteria during the open-label period will be randomized (1:1) to the double-blind period to continue treatment with axs-05 or switch to treatment with bupropion (105 mg) tablets. randomized subjects will receive double-blind treatment for 26 weeks or until they experience a relapse.

Eligibility criteria:
inclusion criteria: * currently meets dsm-5 criteria for diagnosis of mdd without psychotic features * current major depressive episode of at least 4 weeks in duration exclusion criteria: * previously participated in another clinical study of axs-05; received any investigational drug or device treatment within 30 days of (screening) visit 1, or has been prescribed auvelity. * unable to comply with study procedures * medically inappropriate for study participation in the opinion of the investigator

Keywords: axs-05 dextromethorphan bupropion mdd depression relapse of depressive symptoms nmda receptor antagonist sigma-1 receptor agonist norepinephrine reuptake inhibitor dopamine reuptake inhibitor axsome therapeutics
pazopanib (gw786034) in subjects with relapsed or refractory multiple myeloma

Conditions: Carcinoma, Renal Cell

Summary: the purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. the treatment involves daily dosing. a patient may continue to receive the treatment as long as they are benefiting from the treatment. blood samples will be taken at specific times to measure the amount of drug in your body at specific times after the drug is given. blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. physical exams will be performed before each treatment. during the treatment phase, the patients will undergo regular assessments for safety and clinical response.


Eligibility criteria:
inclusion criteria: * must have diagnosis of relapsed or refractory multiple. * bone marrow function \[anc (absolute neutrophil count) greater than 1000/mm3\]; platelet count greater than or equal to 75,000/mm3. * renal function (calculated creatinine clearance \>50 ml.min, albumin less than or equal to 500 mg). exclusion criteria: * failed more than 3 prior lines of therapy including stem cell transplant. * females who are pregnant or nursing. * unstable blood pressure. * significant heart conditions or history of thrombosis. * any unstable, pre-existing major medical condition or history of other cancers. * have received an investigational drug, chemotherapy, radiation treatment or surgery within 28 days prior to entering the study.

Keywords: pazopanib(gw786034) solid tumors myeloma
obstructive sleep apnea (osa) in pulmonary arterial hypertension (pah)

Conditions: Pulmonary Arterial Hypertension; Obstructive Sleep Apnea

Summary: the purpose of this study is to determine whether pulmonary arterial hypertension can worsen or even cause sleep apnea. it is hypothesized that if pulmonary arterial hypertension does indeed worsen or cause sleep apnea, then the treatment should first focus on the underlying pulmonary arterial hypertension instead of the sleep apnea. to determine if a person has sleep apnea, they will undergo one overnight polysomnogram (sleep study). if it is found that they have mild to moderate sleep apnea, then the subject will be invited to continue in the study and their pulmonary arterial hypertension will be treated by their managing primary physician. after the subject has had treatment for their pulmonary arterial hypertension, the study center will have them return for a follow up sleep study to learn the effects of pulmonary arterial hypertension treatment management on their sleep apnea, 12-24 weeks after the first sleep study.

pulmonary arterial hypertension (pah) is associated with fluid retention. currently, the treatment paradigm for newly diagnosed pah patients includes evaluation for obstructive sleep apnea (osa). the investigators propose that untreated or sub-optimally managed pah patients have significant fluid retention which redistributes to the upper body during sleep and exacerbates or even mimics osa. the investigators hypothesize that treatment of pah patients with vasodilators and diuretics to optimize fluid balance will attenuate or even resolve osa prior to the initiation of specific therapy for osa (cpap).

Eligibility criteria:
inclusion criteria: * • diagnosis of group 1 pah * either lack of treatment for pah or sub-optimally treated pah as defined by nyha fc 3 or 4 * age 18 or older * ability to give consent * ability to undergo overnight polysomnogram * previously diagnosed osa not on therapy exclusion criteria: * age younger than 18 * pregnancy * previously diagnosed osa and receiving therapy * inability to undergo overnight polysomnography in laboratory

Keywords: obstructive sleep apnea, , pulmonary arterial hypertension sleep study, polysomnogram, respiratory disturbance index (rdi)
efficacy and safety study of miconazole lauriad to treat oropharyngeal candidiasis in hiv patients

Conditions: HIV Infections

Summary: the purpose of this study is to evaluate the clinical cure of miconazole lauriad 50 mg (1x50mg) bioadhesive buccal tablets compared with clotrimazole troches (5x10mg) after 14 days of treatment (at the test of cure visit, at day 17-19).


Eligibility criteria:
inclusion criteria: * patients with clinical picture of oropharyngeal candidiasis * confirmation of oropharyngeal candidiasis by candida culture positive * hiv-positive patients * patients 18 years of age exclusion criteria: * patients with signs or symptoms of systemic candidiasis * patients with signs or symptoms of esophagitis * pregnant or breast-feeding women * patients who have taken systemic antifungals within the past 30 days * patients who have taken local antifungals within the past 7 days

Keywords: miconazole lauriad oropharyngeal candidiasis hiv patients mycology clinical picture of oropharyngeal candidiasis candida culture positive treatment experienced
open-label trial of atomoxetine to evaluate academic outcome in children ages 8-11 years with attention deficit/hyperactivity disorder

Conditions: Attention Deficit Hyperactivity Disorder

Summary: open-label trial of atomoxetine to evaluate academic outcome in children ages 8-11 years with attention- deficit/hyperactivity disorder


Eligibility criteria:
inclusion criteria: -patients must have adhd, be psychotropic medication naive and be outpatients who are at least 8 years of age and not more than 10 years of age at visit 1 (that is, not yet reached their 11 birthday) so that all year testing will be completed before the child reaches age 12. exclusion criteria: -patients with current or past history of bipolar i or ii disorder, psychosis, autism, asperger's syndrome, pervasive developmental disorder, conduct disorder, seizure disorder or serious suicidal risk are excluded
therapeutic effects of compound zhenzhu tiaozhi capsules in nafld

Conditions: Nonalcoholic Fatty Liver Disease

Summary: this is a randomised clinical trial which aims to evaluate the efficacy of compound zhenzhu tiaozhi capsules in the treatment of nafld and analyze the relationship between improvement in nafld parameters and changes in intestinal functions.

this is a randomised clinical trial which aims to evaluate the efficacy of compound zhenzhu tiaozhi capsules in the treatment of nafld and analyze the relationship between improvement in nafld parameters and changes in intestinal functions. in this study, the investigators will (1)evaluate the relationship between the function of intestinal mucosal barrier, sibo, and nafld;(2)assess the effects of compound zhenzhu tiaozhi capsules on intrahepatic fat content, hepatic noninvasive score, liver biochemical parameters, blood lipid, and insulin resistance. to evaluate the therapeutic effects of compound zhenzhu tiaozhi capsules on the treatment of nafld, and determine whether the risk stratification of atherosclerotic cardiovascular disease (ascvd) and quality of life (using the 36-item short form health survey \[sf-36\]) can be improved in nafld patients with compound zhenzhu tiaozhi capsules;(3) compare the therapeutic effects of compound zhenzhu tiaozhi capsules with conventional medications in the treatment of nafld, and to compare their efficacies in improving the risk stratification of ascvd and quality of life, as assessed by the sf-36; (4) analyze the relationship of compound zhenzhu tiaozhi capsules in improving nafld and parameters related to the function of the intestinal mucosal barrier and sibo.

Eligibility criteria:
inclusion criteria: clinical diagnosis of simple steatosis or nash 18 to 75 years old serum alanine transaminase (alt)≤2 times the upper limit of normal exclusion criteria: other chronic liver diseases serious complications in other organs malignant tumors
clinical and radiographic evaluation of laser photobiomodulation pulpotomy of primary molars in children

Conditions: Pulpitis; Pulpotomy

Summary: this study aimed to evaluate the clinical and radiographic outcomes of photobiomodulation pulpotomy compared to mta pulpotomy in primary molars in children.


Eligibility criteria:
inclusion criteria: * children with dental behavior score of 3 or 4 according to the frankel behavior rating scale. * patients whom their maxillary primary molars are indicated for pulpotomy and ssc restoration. * lack of history of allergy to the materials used for anesthesia and sulfite. * children free of any systemic disease or special health care needs (asa 1). * completion of the written informed consent form by parents/guardian. exclusion criteria: * children who receive any analgesic drugs at least 24 hours before treatment. * any inflammation or lesion in the injection site * patients who have previous bad experience of dentistry were excluded to eliminate the possible impact of the child's previous painful or stressful experiences * child coming for emergency treatment of pain. * if hemostasis is not achieved within five minutes after application of moist cotton pellet directly to the pulp stumps * if radicular pulp tissue was not vital due to the presence of suppuration or purulent necrosis (pus discharge).